Literature DB >> 26957055

The effect of urapidil, an alpha-1 adrenoceptor antagonist and a 5-HT1A agonist, on the vascular tone of the porcine coronary and pulmonary arteries, the rat aorta and the human pulmonary artery.

Claire Bopp1, Cyril Auger2, Pierre Diemunsch3, Valérie Schini-Kerth4.   

Abstract

Urapidil (Eupressyl(®)) an antihypertensive drug acting as an α1 antagonist and a 5-HT1A agonist, may be of special interest in the treatment of hypertension associated with preeclamptic toxaemia and hypoxia-induced pulmonary arterial vasoconstriction. However, the effect of urapidil on vascular tone has been poorly investigated. Vascular reactivity was evaluated using pulmonary and coronary arteries from 36 pigs, aortae from 22 rats and 9 human pulmonary artery samples suspended in organ chambers. Concentration-relaxation curves either to urapidil, 5-HT, or the 5-HT1A receptor agonist 8-OH-DPAT were constructed after pre-contraction of rings. Pig pulmonary and coronary artery rings were contracted with U46619, a thromboxane mimetic, rat aortic rings with either endothelin-1 or phenylephrine, and human pulmonary artery rings with U46619 or phenylephrine. Urapidil markedly inhibited phenylephrine-induced contractions in rat aortic rings with and without endothelium with a more pronounced effect observed in rings without endothelium. Both 5-HT and 8-OH-DPAT failed to induce relaxation in rat aortic rings with an intact endothelium. 5-HT, but not urapidil and 8-OH-DPAT, induced a concentration-dependent relaxation in the porcine coronary and pulmonary artery rings with an intact endothelium (P<0.05). 5-HT and phenylephrine but not urapidil caused concentration-dependent contractions in human pulmonary artery rings. The present findings, while confirming that urapidil is a potent inhibitor of α1-adrenoceptor-induced contraction, do not support the role of 5-HT1A receptor activation in the control of the vascular tone of the different types of arteries tested in response to urapidil. In addition, they indicate that urapidil seems to preferentially target arteries with endothelial dysfunction.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-HT1A agonist; Alpha-1 adrenoceptor antagonist; Antihypertensive drug; Urapidil; Vascular reactivity

Mesh:

Substances:

Year:  2016        PMID: 26957055     DOI: 10.1016/j.ejphar.2016.03.012

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  Relationship between myocardial oxygenation and blood pressure: Experimental validation using oxygenation-sensitive cardiovascular magnetic resonance.

Authors:  Dominik P Guensch; Kady Fischer; Christof Jung; Samuel Hurni; Bernhard M Winkler; Bernd Jung; Andreas P Vogt; Balthasar Eberle
Journal:  PLoS One       Date:  2019-01-16       Impact factor: 3.240

Review 2.  Monoaminergic Receptors as Modulators of the Perivascular Sympathetic and Sensory CGRPergic Outflows.

Authors:  Bruno A Marichal-Cancino; Abimael González-Hernández; Enriqueta Muñoz-Islas; Carlos M Villalón
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

3.  Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta-analysis.

Authors:  Jiaxiao Shi; Yulin Li; Cong Xing; Peng Peng; Hongyu Shi; Han Ding; Pengyuan Zheng; Guangzhi Ning; Shiqing Feng
Journal:  Drug Des Devel Ther       Date:  2018-12-27       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.